Non-invasive fetal genetic screening by digital analysis
View Patent ↗The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital analysis is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.
1. A method for identifying a risk for an aneuploidy on a first chromosome of a fetus carried by a euploid mother, the method comprising:
a) distributing a sample of nucleic acids into at least 500 discrete locations, wherein said sample is derived from a cell-free portion of a maternal blood sample that contains a mixture of maternal and fetal DNA;
b) amplifying said nucleic acids at said discrete locations, wherein each of said discrete locations contains, on average, not more than about one target sequence per discrete location;
c) determining a first value by counting a number of detected sequences at the at least 500 locations representing a first location on the first chromosome, wherein counting comprises detecting fluorescently-labeled probes hybridized to the amplified nucleic acids at said discrete locations, wherein the first value:
i) includes a contribution from detection of the maternal DNA and the fetal DNA, and
ii) is not based on separately determining contributions to the amount at the first location from the maternal DNA and the fetal DNA;
d) determining a second value by counting a number of detected sequences at the at least 500 locations representing a second location on the second chromosome which is presumed to be euploid, wherein counting comprises detecting fluorescently-labeled probes hybridized to the amplified nucleic acids at said discrete locations, wherein the second value:
i) includes a contribution from detection of the maternal DNA and the fetal DNA; and
ii) is not based on separately determining contributions to the amount at the second location from the maternal DNA and the fetal DNA; and
e) determining a difference between the first value and the second value, wherein a statistically significant difference indicates the presence of aneuploidy on the first chromosome in the fetal DNA.
2. The method of claim 1 , further comprising:
a) determining a third value for an amount of a third target sequence at a third location on a third chromosome at the at least 500 locations, wherein the third value:
i) includes a contribution from detection of the maternal DNA and the fetal DNA; and
ii) is not based on separately determining contributions to the amount at the second location from the maternal DNA and the fetal DNA; and
b) determining differences among the first value, the second value, and the third value, wherein a statistically significant difference indicates the presence of aneuploidy on the first chromosome in the fetal DNA.
3. The method of claim 1 , further comprising:
a) determining multiple values for multiple target sequences at multiple different locations on the first chromosome at the at least 500 locations; and
b) determining multiple values for multiple target sequences at multiple different locations on the second chromosome at the at least 500 locations,
wherein determining a difference between the multiple values on the first chromosome and the multiple values on the second chromosome comprises analyzing for aneuploidy of the first chromosome in the fetus using the multiple values for the multiple target sequences at the multiple different locations on the first chromosome and the multiple values for the multiple target sequences at the multiple different locations on the second chromosome.
4. The method of claim 3 , wherein the multiple target sequences at multiple different locations on the first chromosome and the multiple target sequences at multiple different locations on the second chromosome are detected using probes directed to the locations on the first and second chromosomes.
5. The method of claim 3 , further comprising summing the values for the multiple target sequences at multiple different locations on the first chromosome to provide a value for the first chromosome, wherein determining a difference between the multiple values on the first chromosome and the multiple values on the second chromosome comprises analyzing for aneuploidy of the first chromosome in the fetus using the value for the first chromosome.
6. The method of claim 1 , wherein determining a statistically significant difference between the first value and the second value comprises a t test.
7. The method of claim 1 , wherein the amplifying and determining comprise digital PCR.
8. The method of claim 1 , wherein determining a statistically significant difference between the first value and the second value comprises comparing:
a) a ratio of a value for the first chromosome to a value for one or more chromosomes including the second chromosome, wherein said values are derived from detection reactions on the maternal blood sample being tested; and
b) a value based on multiple ratios of a value for the first chromosome to a value for one or more chromosomes including the second chromosome, wherein said values are derived from analysis of multiple other maternal samples.
9. The method of claim 1 , wherein determining a statistically significant difference between the first value and the second value further comprises taking into account the fraction level of fetal DNA in the sample of nucleic acids, according to the formula
N =( k /(ε(α− e ))) 2
wherein k represents the number of standard deviations, N represents the number of discrete locations, □ represents the fetal fraction, α represents the order of aneuploidy, and e represents the order of euploidy.
10. A method for identifying a risk for an aneuploidy on a first chromosome of a fetus carried by a euploid mother, the method comprising:
a) distributing a sample of nucleic acids into at least 500 discrete locations, wherein said sample is derived from a cell-free portion of a maternal blood sample that contains a mixture of maternal and fetal DNA;
b) amplifying said nucleic acids at said discrete locations, wherein each of said discrete locations contains, on average, not more than about one target sequence per discrete location;
c) determining first multiple values by counting a number of detected sequences at multiple different locations on the first chromosome at the at least 500 locations, wherein counting comprises detecting fluorescently-labeled probes hybridized to the amplified nucleic acids at said discrete locations, wherein the first multiple values:
i) include a contribution from detection of the maternal DNA and the fetal DNA; and
ii) are not based on separately determining contributions to the amounts at the multiple different locations on the first chromosome from the maternal DNA and the fetal DNA; and
d) determining second multiple values by counting a number of detected sequences at multiple different locations on the second chromosome which is presumed to be euploid at the at least 500 locations, wherein counting comprises detecting fluorescently-labeled probes hybridized to the amplified nucleic acids at said discrete locations, wherein the second multiple values:
i) include a contribution from detection of the maternal DNA and the fetal DNA; and
ii) are not based on separately determining contributions to the amounts at the multiple different locations on the second chromosome from the maternal DNA and the fetal DNA; and
e) determining a difference between the first multiple values, and the second multiple values wherein a statistically significant difference indicates the presence of aneuploidy on the first chromosome in the fetal DNA.
11. The method of claim 10 , further comprising:
a) determining a third value for an amount of a third target sequence at a location on a third chromosome at the at least 500 locations, wherein the third value:
i) includes a contribution from detection of the maternal DNA and the fetal DNA;
ii) is not based on separately determining contributions to the amount at the location on the third chromosome from the maternal DNA and the fetal DNA; and
b) determining a difference between the first multiple values, the second multiple values and the third value to analyze for aneuploidy of the first chromosome in the fetus using the third value.
12. The method of claim 10 , wherein determining the difference between the first multiple values and the second multiple values comprises comparing:
a) a ratio of a value for the first chromosome to a value for one or more chromosomes, wherein said value includes the second chromosome derived from detection reactions on the sample of nucleic acids; and
b) a value based on multiple ratios of a value for the first chromosome to a value for one or more chromosomes including the second chromosome, wherein said values are derived from analysis of multiple other maternal samples.
13. The method of claim 10 , wherein determining the difference between the first multiple values and the second multiple values further comprises taking into account the fraction level of fetal DNA in the sample of nucleic acids, according to the formula
N =( k /(ε(α− e ))) 2
wherein k represents the number of standard deviations, N represents the number of discrete locations, ε represents the fetal fraction, α represents the order of aneuploidy and e represents the order of euploidy.
14. The method of claim 10 , further comprising summing the first multiple values to provide a value for the first chromosome, wherein determining the difference between the first multiple values and the second multiple values comprises analyzing for aneuploidy of the first chromosome in the fetus using the value for the first chromosome.